More antibiotics, more danger for cirrhosis patients

A prospective cohort study out of Germany has found that the more antibiotics patients with advanced chronic liver disease receive, the greater their risk of picking up multidrug-resistant organisms (MDROs) — and that newly acquired resistance is tied to a significantly higher risk of death.

The study tracked 256 patients treated at a Frankfurt center between 2020 and 2023. Among the 246 who were MDRO-free at first admission, nearly 20% acquired vancomycin-resistant enterococci (VRE) and about 11% acquired resistant Gram-negative bacteria during follow-up. Crucially, newly detected MDROs — but not those present at baseline — were independently associated with a more than twofold increase in 180-day mortality.

By the Numbers:

• 19.9% of patients acquired VRE during follow-up
• 11.4% acquired resistant Gram-negative bacteria
• VRE acquisition risk hit 20% at just 9.6 cumulative defined daily doses of any antibiotic — and as low as 1.5 doses for glycopeptides
• New MDRO acquisition was linked to a hazard ratio of 2.15 for 180-day mortality (P = .004)

Why it matters: These findings push back against one-size-fits-all antibiotic duration guidelines. For clinicians managing decompensated cirrhosis, cumulative antibiotic exposure — not just treatment length — should drive daily prescribing decisions, with class-specific thresholds prompting earlier reassessment, de-escalation, or narrowing of therapy.